Preethi Sridhar, MD
Endocrinology, Diabetes & Metabolism · Mountain View, CANPI 1033362041
Payments from drug & device makers
Across 311 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Boehringer Ingelheim$821
- Novo Nordisk$813
- Amgen$697
- Radius Health, Inc.$473
- Sanofi-aventis U.S. LLC$313
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $1,199 |
| Boehringer Ingelheim | 36 | $821 |
| Novo Nordisk | 41 | $813 |
| Amgen(2 entities) | 28 | $697 |
| Radius Health, Inc. | 19 | $473 |
| Sanofi-aventis U.S. LLC | 14 | $313 |
| Abbott | 14 | $312 |
| Madrigal Pharmaceuticals | 10 | $255 |
| BETA Bionics, Inc. | 5 | $254 |
| AbbVie | 12 | $238 |
| Mannkind Corporation | 10 | $236 |
| AstraZeneca(2 entities) | 11 | $230 |
| Dexcom, Inc. | 9 | $227 |
| Bayer | 7 | $182 |
| Xeris Pharmaceuticals, Inc. | 7 | $130 |
| Medtronic(2 entities) | 5 | $113 |
| Kyowa Kirin, Inc. | 3 | $78 |
| Embecta Corp. | 3 | $71 |
| Shire North American Group Inc | 3 | $66 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Ascensia Diabetes Care US Inc. | 3 | $57 |
| Tandem Diabetes Care, Inc. | 2 | $57 |
| Soleno Therapeutics, Inc. | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $42 |
| Insulet Corporation | 2 | $40 |
| BD | 1 | $37 |
| Cequr Corporation | 1 | $35 |
| Sequel Med Tech, LLC | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $27 |
| Alfasigma USA, Inc. | 1 | $27 |
| Exact Sciences | 1 | $25 |
| Pfizer | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Bigfoot Biomedical Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,340 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HumatropeSomatropin | 15 | $109,396 |
| OzempicSemaglutide | 36 | $65,397 |
| JardianceEmpagliflozin | 34 | $52,841 |
| TymlosAbaloparatide | 12 | $46,610 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $16,188 |
| MounjaroTirzepatide | 17 | $15,965 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 12 | $9,328 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $8,772 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 57 | $6,475 |
| SynthroidLevothyroxine Sodium | 57 | $4,719 |
| Armour ThyroidThyroid,pork | 20 | $2,230 |
| Levothyroxine Sodium | 130 | $1,930 |
| Liothyronine Sodium | 11 | $1,164 |
| Np ThyroidThyroid,pork | 17 | $1,071 |
| Metformin Hcl | 73 | $942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCHumatrope, Mounjaro | $1,199 | $125,36132 claims |
| Novo NordiskOzempic | $813 | $65,39736 claims |
| Boehringer IngelheimJardiance | $821 | $52,84134 claims |
| Radius Health, Inc.Tymlos | $473 | $46,61012 claims |
| AbbVieSynthroid, Armour Thyroid | $238 | $6,94977 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $20 | $1,07117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Mountain View
- Michael GreenfieldMountain View$631K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.